Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Postexposure Prophylaxis

Source: Key Decisions in HIV Care
Listen as Dr Michelle D. Collins-Ogle shares data and recommendations for HIV PEP, including currently recommended regimens, single-tablet regimens, and pre-exposure prophylaxis following PEP.
Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS
Released: May 26, 2022

In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores the data and recommendations for HIV postexposure prophylaxis (PEP).

Listen as she gives perspectives on:

  • The CDC algorithm for evaluation and treatment of potential HIV exposures
  • The CDC guideline preferred and alternative PEP antiretroviral therapy regimens
  • Data for the use of the single-tablet regimen bictegravir/emtricitabine/tenofovir alafenamide for PEP
  • Recommended laboratory monitoring with PEP

Information on this Educational Activity

Faculty

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS

Assistant Professor of Pediatrics
Division of Pediatric Infectious Diseases
Pediatric and Adolescent HIV
Children’s Hospital at Montefiore
Pediatric Hospital of Albert Einstein
College of Medicine
Bronx, New York

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings